Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: A case of clinical and diagnostic challenges

Transplant Infectious Disease

Volumn 13, Issue 5, 2011, Pages 524-530

  Kittan, N A ^a   Beier, F ^a   Kurz, K ^a   Niller, H H ^a   Egger, L ^a   Jilg, W ^a   Andreesen, R ^a   Holler, E ^a   Hildebrandt, G C ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Allogeneic stem cell transplantation; Central nervous system; EBV; Encephalitis; Epstein Barr virus; Post transplant lymphoproliferative disorder; PTLD

Indexed keywords

CARMUSTINE; CYCLOSPORIN; FLUDARABINE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN HEAVY CHAIN; MELPHALAN; MYCOPHENOLIC ACID; PREDNISOLONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ATAXIA; CASE REPORT; CLINICAL FEATURE; CLONAL VARIATION; CONFUSION; CYTOMEGALOVIRUS INFECTION; DEATH; DIAGNOSTIC IMAGING; DIPLOPIA; DONOR LYMPHOCYTE INFUSION; ENCEPHALITIS; EPSTEIN BARR VIRUS INFECTION; HUMAN; IMAGE ANALYSIS; LYMPHOPROLIFERATIVE DISEASE; MALE; NEUROIMAGING; POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; SYMPTOM;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BRAIN; ENCEPHALITIS, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FATAL OUTCOME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED;

EID: 80053618534     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2011.00621.x     Document Type: Article

References (44)

1. Kutok JL, Wang F. Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol 2006; 1: 375-404.
2. Portegies P, Corssmit N. Epstein-Barr virus and the nervous system. Curr Opin Neurol 2000; 13 (3): 301-304.
3. Schellinger PD, Sommer C, Leithauser F, et al. Epstein-Barr virus meningoencephalitis with a lymphoma-like response in an immunocompetent host. Ann Neurol 1999; 45 (5): 659-662.
4. Volpi A. Epstein-Barr virus and human herpesvirus type 8 infections of the central nervous system. Herpes 2004; 11 (Suppl 2): 120A-127A.
5. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 2000; 13 (2): 193-207.
6. Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009; 113 (20): 4992-5001.
7. Meij P, van Esser JW, Niesters HG, et al. Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003; 101 (11): 4290-4297.
8. Buell JF, Gross TG, Hanaway MJ, et al. Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc 2005; 37 (2): 954-955.
9. Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010; 28 (6): 1038-1046.
10. Leblond V, Dhedin N, Mamzer Bruneel MF, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001; 19 (3): 772-778.
11. Aisa Y, Mori T, Nakazato T, et al. Primary central nervous system post-transplant lymphoproliferative disorder presenting as cerebral hemorrhage after unrelated bone marrow transplantation. Transpl Infect Dis 2009; 11 (5): 438-441.
12. Castellano-Sanchez AA, Li S, Qian J, Lagoo A, Weir E, Brat DJ. Primary central nervous system posttransplant lymphoproliferative disorders. Am J Clin Pathol 2004; 121 (2): 246-253.
13. Hamadani M, Martin LK, Benson DM, Copelan EA, Devine SM, Hofmeister CC. Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein-Barr virus DNA PCR. Bone Marrow Transplant 2007; 39 (4): 249-251.
14. Kordelas L, Trenschel R, Koldehoff M, Elmaagacli A, Beelen DW. Successful treatment of EBV PTLD with CNS lymphomas with the monoclonal anti-CD20 antibody rituximab. Onkologie 2008; 31 (12): 691-693.
15. Nagafuji K, Eto T, Hayashi S, et al. Donor lymphocyte transfusion for the treatment of Epstein-Barr virus-associated lymphoproliferative disorder of the brain. Bone Marrow Transplant 1998; 21 (11): 1155-1158.
16. Terasawa T, Ohashi H, Tsushita K, et al. Failure to detect Epstein-Barr virus (EBV) DNA in plasma by real-time PCR in a case of EBV-associated posttransplantation lymphoproliferative disorder confined to the central nervous system. Int J Hematol 2002; 75 (4): 416-420.
17. O'Neill BP, Vernino S, Dogan A, Giannini C. EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil. Neuro Oncol 2007; 9 (3): 364-369.
18. Peres E, Savasan S, Klein J, Abidi M, Dansey R, Abella E. High fatality rate of Epstein-Barr virus-associated lymphoproliferative disorder occurring after bone marrow transplantation with rabbit antithymocyte globulin conditioning regimens. J Clin Microbiol 2005; 43 (7): 3540-3543.
19. Angelini L, Bugiani M, Zibordi F, Cinque P, Bizzi A. Brainstem encephalitis resulting from Epstein-Barr virus mimicking an infiltrating tumor in a child. Pediatr Neurol 2000; 22 (2): 130-132.
20. Behr J, Schaefer M, Littmann E, Klingebiel R, Heinz A. Psychiatric symptoms and cognitive dysfunction caused by Epstein-Barr virus-induced encephalitis. Eur Psychiatry 2006; 21 (8): 521-522.
21. Dellemijn PL, Brandenburg A, Niesters HG, van den Bent MJ, Rothbarth PH, Vlasveld LT. Successful treatment with ganciclovir of presumed Epstein-Barr meningo-encephalitis following bone marrow transplant. Bone Marrow Transplant 1995; 16 (2): 311-312.
22. Garamendi I, Montejo M, Cancelo L, et al. Encephalitis caused by Epstein-Barr virus in a renal transplant recipient. Clin Infect Dis 2002; 34 (2): 287-288.
23. Khalil M, Enzinger C, Wallner-Blazek M, et al. Epstein-Barr virus encephalitis presenting with a tumor-like lesion in an immunosuppressed transplant recipient. J Neurovirol 2008; 14 (6): 574-578.
24. Baskin HJ, Hedlund G. Neuroimaging of herpesvirus infections in children. Pediatr Radiol 2007; 37 (10): 949-963.
25. DeBiasi RL, Kleinschmidt-DeMasters BK, Weinberg A, Tyler KL. Use of PCR for the diagnosis of herpesvirus infections of the central nervous system. J Clin Virol 2002; 25 (Suppl 1): S5-S11.
26. van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001; 98 (4): 972-978.
27. Weinberger B, Plentz A, Weinberger KM, Hahn J, Holler E, Jilg W. Quantitation of Epstein-Barr virus mRNA using reverse transcription and real-time PCR. J Med Virol 2004; 74 (4): 612-618.
28. Styczynski J, Reusser P, Einsele H, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009; 43 (10): 757-770.
29. Cavaliere R, Petroni G, Lopes MB, Schiff D. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer 2010; 116 (4): 863-870.
30. Hanel M, Fiedler F, Thorns C. Anti-CD20 monoclonal antibody (Rituximab) and Cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement. Onkologie 2001; 24 (5): 491-494.
31. Nozzoli C, Bartolozzi B, Guidi S, et al. Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 2006; 47 (1): 167-169.
32. Oertel SH, Anagnostopoulos I, Hummel MW, Jonas S, Riess HB. Identification of early antigen BZLF1/ZEBRA protein of Epstein-Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease. Br J Haematol 2002; 118 (4): 1120-1123.
33. Reshef R, Tsai DE. Rituximab for PTLD of the CNS: is it a 'no-brainer'? Onkologie 2008; 31 (12): 650-651.
34. Ruhstaller TW, Amsler U, Cerny T. Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma? Ann Oncol 2000; 11 (3): 374-375.
35. van de Glind G, de Graaf S, Klein C, Cornelissen M, Maecker B, Loeffen J. Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system. Pediatr Blood Cancer 2008; 50 (4): 886-888.
36. de Beukelaar JW, van Arkel C, van den Bent MJ, et al. Resolution of EBV(+) CNS lymphoma with appearance of CSF EBV-specific T cells. Ann Neurol 2005; 58 (5): 788-792.
37. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330 (17): 1185-1191.
38. Wynn RF, Arkwright PD, Haque T, et al. Treatment of Epstein-Barr-virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation. Lancet Oncol 2005; 6 (5): 344-346.
39. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115 (5): 925-935.
40. Pakakasama S, Eames GM, Morriss MC, et al. Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation 2004; 78 (5): 755-757.
41. Moosmann A, Bigalke I, Tischer J, et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 2010; 115 (14): 2960-2970.
42. Nabors LB, Palmer CA, Julian BA, Przekwas AM, Kew CE. Isolated central nervous system posttransplant lymphoproliferative disorder treated with high-dose intravenous methotrexate. Am J Transplant 2009; 9 (5): 1243-1248.
43. Lee KH, Lee JH, Choi SJ, et al. Failure of trilineage blood cell reconstitution after initial neutrophil engraftment in patients undergoing allogeneic hematopoietic cell transplantation - frequency and outcomes. Bone Marrow Transplant 2004; 33 (7): 729-734.
44. Heslop HE. How I treat EBV lymphoproliferation. Blood 2009; 114 (19): 4002-4008.